Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy

Xuan, Xiuyun; Zhang, Lin; Tian, Chunxia; Wu, Ting; Ye, Haihua; Cao, Juanmei; Chen, Fangqi; Liang, Yan; Yang, Haowen; Huang, Changzheng

doi:10.1186/s13578-020-00504-1

Cited by 17 publications

(15 citation statements)

References 90 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding, if confirmed in the prospective study, may be of clinical importance in the real world of rheumatology practice, where no diagnostic criteria for AxSpA exist, and the opinion shown to be an integral part of the mechanisms of some immunemediated diseases and is probably a marker of the osteogenic differentiation of mesenchymal stem cells and new bone formation in AS. [13][14][15] Because of its broad involvement in the pathogenesis of various autoimmune and inflammatory disorders, serum IL-22 cannot differentiate between AxSpA and rheumatoid arthritis, or another inflammatory disorder. 12 However, its place in the differentiation of an inflammatory disease, such as AxSpA, from its non-inflammatory mimickers can be compelling.…”

Section: Discussionmentioning

confidence: 99%

The association between elevated serum interleukin‐22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study

et al. 2021

View full text Add to dashboard Cite

Objective: There is an unmet need for a reliable biomarker for the differentiation of axial spondyloarthritis (AxSpA) from its mimickers. Serum levels of interleukin-22 (IL-22) have previously been found to be significantly elevated in patients with AxSpA compared with healthy individuals or persons with osteoarthritis.Methods: Consecutive patients with established or suspected AxSpA were enrolled.The clinical data, as well as results of laboratory and imaging studies, were acquired from patients' charts. The final diagnosis of definite or probable SpA, or an alternative diagnosis, was determined, and the serum levels of IL-22 were examined by enzyme-linked immunosorbent immunoassay.Results: Interleukin-22 levels were significantly higher in patients with definite AxSpA (29 patients) compared with patients with alternative diagnoses (14 patients) and healthy volunteers (16 individuals; P < 0.001 for both comparisons). The sensitivity and specificity of the serum IL-22 for the AxSpA diagnosis were 0.68 (95% CI 0.49-0.84) and 0.86 (95% CI 0.68-0.95), respectively, for the cut-off value of 5 pg/ mL. In patients with AxSpA, serum IL-22 levels did not correlate with modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS), or serum C-reactive protein. Conclusion: Serum IL-22 levels are elevated in patients with the clinical diagnosis ofAxSpA and can potentially serve as an independent biomarker for the differentiation of AxSpA from its non-inflammatory mimickers.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between elevated serum interleukin‐22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…IL-22 is a member of the IL-10 family of cytokines produced by Th17 cells, γδ T cells, natural killer cells, and innate lymphoid cells [ 47 , 72 ].…”

Section: Cytokines In Alopecia Areatamentioning

confidence: 99%

The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications

Waśkiel‐Burnat

Osińska

Salińska

et al. 2021

Cells

View full text Add to dashboard Cite

Alopecia areata is a type of non-scarring hair loss. The dysregulation of numerous systemic Th1 (IL-2, IFN-γ, TNF, IL-12, and IL-18), Th2 (IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17E, IL-31 and IL-33) and Th17 (IL-17, IL-17F, IL-21, IL-22, IL-23 and TGF-β) cytokines was observed in patients with alopecia areata. Positive correlations between the severity of alopecia areata and an increased serum level of various cytokines including IL-2, TNF, IL-12, IL-17, and IL-17E were reported in the literature. An increased serum level of numerous cytokines, such as IL-2, IL-6, TNF, IL-12, IL-17E, and IL-22, was described as positively correlated with the duration of the disease. Moreover, it was shown that increased pre-treatment serum level of IL-12 was a positive, while increased serum levels of IL-4 and IL-13 were negative prognostic markers for the efficacy of diphenylcyclopropenone. In conclusion, alopecia areata is associated with the dysregulation of systemic Th1, Th2 and Th17 cytokines with their role in the pathogenesis, clinical manifestations and prognosis of the disease. Available data indicate the most significant role of serum IL-2, TNF, IL-12, IL-17, and IL-17E as markers of disease activity. The serum levels IL-4, IL-12 and IL-13 may be useful as potential predictors of diphenylcyclopropenone efficacy.

show abstract

“…Connective tissue disease (CTD) encompasses a group of systematic inflammatory diseases, including idiopathic inflammatory myopathy (IIM), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), all of which may share common pathogenic mechanisms and multiorgan involvement including the heart [1][2][3][4]. Cardiac involvement in patients with CTD represents one of the leading causes of death [4,5].…”

Section: Introductionmentioning

confidence: 99%

Quantitative assessment of left ventricular myocardial involvement in patients with connective tissue disease: a 3.0T contrast-enhanced cardiovascular magnetic resonance study

Wang

Gao

Yang

et al. 2022

Int J Cardiovasc Imaging

View full text Add to dashboard Cite

The aim of this study was to evaluate left ventricular (LV) myocardial involvement in connective tissue disease (CTD) patients using multiparemetric imaging derived from cardiovascular magnetic resonance (CMR). CMR was performed on 146 CTD patients (comprising of 74 with idiopathic inflammatory myopathy (IIM) and 72 with non-IIM) and 72 healthy controls and included measures of LV global strains [including peak strain (PS), peak systolic (PSSR) and diastolic strain rate (PDSR)], myocardial perfusion [including upslope, max signal intensity (MaxSI), and time to maximum signal intensity (TTM)], and late gadolinium enhancement (LGE) parameters. Univariable and multivariable linear regression analyses were performed to determine the association between LV deformation and microvascular perfusion, as well as LGE. Our results indicated that CTD patients had decreased global longitudinal PS (GLPS), PSSR, PDSR, and myocardial perfusion (all p < 0.017) compared with normal controls. Non-IIM patients exhibited lower LV global strain and longer TTM than IIM patients. The presence of LGE was independently associated with global radial PS (GRPS: β = − 0.165, p = 0.011) and global circumferential PS (GCPS: β = − 0.122, p = 0.022). TTM was independently correlated with GLPS (β = − 0.156, p = 0.027). GLPS was the best indicator for differentiating CTD patients from normal controls (area under curve of 0.78). This study indicated that CTD patients showed impaired LV global myocardial deformation and microvascular perfusion, and presence of LGE. Cardiac involvement might be more severe in non-IIM patients than in IIM patients. Impaired microvascular perfusion and the presence of LGE were independently associated with LV global deformation.

show abstract

Interleukin-22 and connective tissue diseases: emerging role in pathogenesis and therapy

Cited by 17 publications

References 90 publications

The association between elevated serum interleukin‐22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study

The association between elevated serum interleukin‐22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study

The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications

Quantitative assessment of left ventricular myocardial involvement in patients with connective tissue disease: a 3.0T contrast-enhanced cardiovascular magnetic resonance study

Contact Info

Product

Resources

About